SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

Share Price is delayed by 15 minutes
Get Live Data
2.21    0.00 (0.00%)
Bid:
2.19
Ask:
2.21
Spread: 0.02 (0.913%)
Market Cap: $714.60m
RTW Live PriceLast checked at - London Stock Exchange

Intraday Rtw Biotech Share Chart

Net Asset Value(s)

13 Jun 2022 07:00

RNS Number : 5602O
RTW Venture Fund Limited
13 June 2022
 

LEI: 549300Q7EXQQH6KF7Z84

13 June 2022

RTW Venture Fund Limited

Net Asset Value

RTW Venture Fund Limited (the "Company") announces that the unaudited net asset value attributable to the ordinary shares of the Company at the close of business on 31 May 2022 (the "NAV") was US$258.3 million, or US$1.22 per ordinary share.

As at 31 May 2022, 33.7 per cent. of the total NAV was invested in privately-held core portfolio companies and 29.3 per cent. of the total NAV was invested in public core portfolio companies, most of which were initiated as private investments.

For Further Information:

RTW Investments, LP

+1 (646) 343 9280

Stephanie Sirota, Chief Business Officer

 

Woody Stileman, Managing Director, Strategic Partnerships

 

 

 

Elysium Fund Management Limited

+44 (0) 14 8181 0100

Joanna Duquemin Nicolle, Chief Executive Officer

 

Sadie Morrison, Managing Director

 

 

 

Morgan Stanley Fund Services USA LLC

+1 (914) 225 8885

 

 

J.P. Morgan Cazenove

+44 (0)20 7742 4000

William Simmonds

 

Jérémie Birnbaum

 

James Bouverat (Sales)

 

 

 

BofA Securities

+44 (0) 20 7628 1000

Edward Peel

 

Kieran Millar

 

 

 

Note:

1.

The NAV is determined by the Company's investment manager, RTW Investments, LP, in accordance with the Company's accounting policies. Investments by the Company in privately-held companies ("Private Portfolio Companies") have been valued at fair market value, taking into account the valuation prepared by Alvarez & Marsal Valuation Services LLC and the nature, facts and circumstances of the Private Portfolio Companies. Investments by the Company in companies listed on a public stock exchange (the "Public Portfolio Companies") have each been valued by reference to their market capitalisation as at close of business on 31 May 2022. The Company applies a valuation discount to its investments in Public Portfolio Companies that are subject to post-IPO lock-up provisions.

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVGPUUAQUPPGMP
Date   Source Headline
17th Jul 20207:00 amRNSIssue of Equity
16th Jul 20206:08 pmRNSAnnouncement of further Share Issuance
16th Jul 20207:00 amRNSIssue of Equity
15th Jul 20207:00 amRNSNet Asset Value(s)
25th Jun 20206:08 pmRNSResult of AGM
22nd Jun 20201:59 pmRNSAGM Statement
16th Jun 20201:15 pmRNSSeries B Financing in C4 Therapeutics
16th Jun 20207:00 amRNSUpdate on Avidity Biosciences IPO
12th Jun 20209:33 amRNSAvidity Biosciences Prices $259.2 Million IPO
12th Jun 20207:00 amRNSNet Asset Value(s)
4th Jun 202012:30 pmRNSSeries B Financing in Athira Pharma
1st Jun 20207:00 amRNSTotal Voting Rights
21st May 20204:00 pmRNSNotice of AGM
19th May 20205:40 pmRNSIssue of Equity
18th May 20207:00 amRNSAnnouncement of Share Issuance
14th May 20207:00 amRNSNet Asset Value(s)
1st May 20207:00 amRNSTotal Voting Rights
28th Apr 20204:36 pmRNSDirector/PDMR Shareholding
28th Apr 20204:29 pmRNSDirector/PDMR Shareholding
27th Apr 20206:27 pmRNSIssue of Equity
27th Apr 202011:40 amRNSIssue of Equity
27th Apr 20207:00 amRNSAnnouncement of further Share Issuance
24th Apr 20206:27 pmRNSIssue of Equity
23rd Apr 20207:00 amRNSAnnouncement of Share Issuance
22nd Apr 20207:01 amRNSPerformance Allocation Share Distribution Deferral
22nd Apr 20207:00 amRNSAnnual Report and Audited Financial Statements
20th Apr 20207:00 amRNSDirector/PDMR Shareholding
17th Apr 20207:00 amRNSQuarterly Update
15th Apr 20206:22 pmRNSNet Asset Value(s)
9th Apr 20204:22 pmRNSNotice of Annual Report
1st Apr 20206:00 pmRNSSeries B2 Financing in iTeos Therapeutics
1st Apr 20204:00 pmRNSName Change of Administrator and Company Secretary
18th Mar 202012:23 pmRNSDirector/PDMR Shareholding
18th Mar 202011:56 amRNSDirector/PDMR Shareholding
13th Mar 20207:00 amRNSNet Asset Value(s)
2nd Mar 20207:00 amRNSTotal Voting Rights
26th Feb 20207:00 amRNSIssue of Equity
19th Feb 20207:00 amRNSIssue of Equity
17th Feb 20205:10 pmRNSAnnouncement of Share Issuance
14th Feb 20207:00 amRNSNet Asset Value(s)
3rd Feb 20207:00 amRNSTotal Voting Rights
29th Jan 20207:00 amRNSIssue of Equity
27th Jan 20207:00 amRNSIssue of Equity
17th Jan 20204:30 pmRNSIssue of Equity
16th Jan 20207:00 amRNSIssue of Equity
15th Jan 20207:00 amRNSNet Asset Value(s)
23rd Dec 201911:28 amRNSHolding(s) in Company
16th Dec 20195:57 pmRNSNet Asset Value(s)
21st Nov 20193:45 pmRNSRTW leads $100M Financing in Avidity Biosciences
5th Nov 201910:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.